Anavex Life Sciences’ (AVXL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report released on Wednesday morning,Benzinga reports. They currently have a $40.00 price objective on the biotechnology company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday.

Anavex Life Sciences Price Performance

Shares of Anavex Life Sciences stock opened at $9.03 on Wednesday. The stock has a market cap of $765.74 million, a PE ratio of -18.10 and a beta of 0.60. The firm has a fifty day moving average price of $6.54 and a 200 day moving average price of $5.62. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $10.45.

Institutional Trading of Anavex Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Anavex Life Sciences by 1.2% in the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock valued at $22,471,000 after acquiring an additional 54,034 shares during the period. Geode Capital Management LLC increased its stake in shares of Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after purchasing an additional 51,946 shares in the last quarter. Nwam LLC acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth about $5,172,000. Charles Schwab Investment Management Inc. lifted its stake in Anavex Life Sciences by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after buying an additional 14,892 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after buying an additional 386,537 shares during the last quarter. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.